In VICTORIES & SUCCESS STORIES on July 29, 2009 at 12:10 pm

No, not the first.  For the record (and this is just scratching the surface):

1.  It’s all complete B.S. of course…as detailed here:


2.  They conveniently left out of the headline that this was “the first FDA approved US located clinical trial”.  The US medical media is great at painting US medical achievements as firsts when in reality, they are 6 yrs behind the rest of the world on stem cell treatments.

3.  Don’t believe it? Here’s the story about my friend James Eilert…treated OUTSIDE THE US in November 2007 –  https://repairstemcell.wordpress.com/2009/07/28/how-people-no-longer-have-to-die-from-heart-failure/ You will also see his remarkable recovery detailed in the (next?) issue of Men’s Journal.

4.  Even with the clarification of #2, someone forget to tell about all those other FDA approved studies underway, like Texas Heart, Vanderbilt, etc.

5.  These from our friend over at Adult Stem Cell Awareness:  This is not the first time a cardiac patient has been treated with stem cells – see: Stem Cells Treat Heart Attack Patient, Adult Stem Cells Better Choice Than Death or Transplant for Heart Failure Patients, Stem Cells Gave Don Ho 15 Extra Months to Perform

6.  And let’s not forget the completed clinical trials at http://clinicatrials.gov

Here are just 5 (completed trials) out of 318 when “heart stem cell” is searched:

********Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease – http://clinicaltrial.gov/ct2/show/NCT00043628?term=stem+cell+heart&rank=4

********Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES – http://clinicaltrial.gov/ct2/show/NCT00291629?term=stem+cell+heart&rank=32

********Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia – http://clinicaltrial.gov/ct2/show/NCT00260338?term=stem+cell+heart&rank=35

********Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2) – http://clinicaltrial.gov/ct2/show/NCT00126100?term=stem+cell+heart&phase=3&rank=8

********The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris – http://clinicaltrial.gov/ct2/show/NCT00135850?term=stem+cell+heart&rank=43

********Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants – http://clinicaltrial.gov/ct2/show/NCT00308633?term=stem+cell+heart&rank=50

and this is one of my favorite…

********Stem Cell Study for Patients With Heart Disease – http://clinicaltrial.gov/ct2/show/NCT00081913?term=stem+cell+heart&rank=58

With more info included here:


1: Circulation. 2007 Jun 26;115(25):3165-72. Epub 2007 Jun 11.

Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD.

Feinberg Cardiovascular Research Institute, and Department of Medicine, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL 60611, USA. d-losordo@northwestern.edu

BACKGROUND: A growing population of patients with coronary artery disease experiences angina that is not amenable to revascularization and is refractory to medical therapy. Preclinical studies have indicated that human CD34+ stem cells induce neovascularization in ischemic myocardium, which enhances perfusion and function.

METHODS AND RESULTS: Twenty-four patients (19 men and 5 women aged 48 to 84 years) with Canadian Cardiovascular Society class 3 or 4 angina who were undergoing optimal medical treatment and who were not candidates for mechanical revascularization were enrolled in a double-blind, randomized (3:1), placebo-controlled dose-escalating study. Patients received granulocyte colony-stimulating factor 5 microg x kg(-1) x d(-1) for 5 days with leukapheresis on the fifth day. Selection of CD34+ cells was performed with a Food and Drug Administration-approved device. Electromechanical mapping was performed to identify ischemic but viable regions of myocardium for injection of cells (versus saline). The total dose of cells was distributed in 10 intramyocardial, transendocardial injections. Patients were required to have an implantable cardioverter-defibrillator or to temporarily wear a LifeVest wearable defibrillator. No incidence was observed of myocardial infarction induced by mobilization or intramyocardial injection. The intramyocardial injection of cells or saline did not result in cardiac enzyme elevation, perforation, or pericardial effusion. No incidence of ventricular tachycardia or ventricular fibrillation occurred during the administration of granulocyte colony-stimulating factor or intramyocardial injections. One patient with a history of sudden cardiac death/ventricular tachycardia/ventricular fibrillation had catheter-induced ventricular tachycardia during mapping that required cardioversion. Serious adverse events were evenly distributed. Efficacy parameters including angina frequency, nitroglycerine usage, exercise time, and Canadian Cardiovascular Society class showed trends that favored CD34+ cell-treated patients versus control subjects given placebo.

CONCLUSIONS: A randomized trial of intramyocardial injection of autologous CD34+ cells in patients with intractable angina was completed that provides evidence for feasibility, safety, and bioactivity. A larger phase IIb study is currently under way to further evaluate this therapy.

Publication Types:

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov’t

PMID: 17562958 [PubMed – indexed for MEDLINE]


First? No, not the first.  Probably up in the thousands by now. – dg

  1. Thanks a lot for the info David.
    Maybe this is why the article by Scientific American didn’t get the publicity it deserved.

  2. It is my understanding – as I posted here: http://adultstemcellawareness.wordpress.com/2009/07/27/man-treated-for-heart-failure-with-own-cardiac-stem-cells/ – that the “first time” here refers to the source of the stem cells that were injected, not the fact that stem cells were used to treat heart failure. This is the “first time” a patient was treated with his own CARDIAC stem cells, rather than stem cells from their blood or bone marrow.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: